0000000000033834

AUTHOR

Gerhard Gründer

showing 67 related works from this author

Equilibrium in [18F]fallypride PET

2010

18F-fallyprideNeurologyChemistryCognitive NeuroscienceRadiochemistryNeuroImage
researchProduct

Mechanism of New Antipsychotic Medications

2003

Antagonism of D 2 -like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80%(striatal) D 2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D 2 -like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is ari…

medicine.medical_specialtyPsychosismedicine.drug_classmedicine.medical_treatmentAripiprazoleAtypical antipsychoticQuinolonesPharmacologyPartial agonistPiperazinesBasal Ganglia DiseasesArts and Humanities (miscellaneous)Dopamine receptor D2Internal medicinemedicineHumansAntipsychoticDose-Response Relationship DrugReceptors Dopamine D2Putamenmedicine.diseaseCorpus StriatumProlactinDopamine D2 Receptor AntagonistsPsychiatry and Mental healthEndocrinologyMechanism of actionDopamine receptorSchizophreniaAripiprazolemedicine.symptomPsychologyAntipsychotic AgentsTomography Emission-Computedmedicine.drugArchives of General Psychiatry
researchProduct

Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression

1993

Roxindole is a potent autoreceptor-“selective” dopamine agonist originally developed for the treatment of schizophrenic syndromes. The drug also inhibits 5-HT uptake and has 5-HT1A agonistic actions. In this open clinical trial 12 in-patients suffering from a major depressive episode (DSM-III-R) were treated with roxindole for 28 days in a fixed dosage of 15 mg per day. A reduction of at least 50% in HAMD-17 total scores was observed in 8 out of 12 patients after 4 weeks (mean HAMD-17 reduction of 56% in all patients), while 4 patients did not respond to roxindole treatment. Half of the patients showed a complete psychopathological remission (HAMD-17 <8). Roxindole's onset of antidepressant…

AdultMaleAgonistIndolesPyridinesmedicine.drug_classPharmacologyDopamine agonistAsymptomaticchemistry.chemical_compoundRoxindoleDopaminemedicineHumansPharmacology (medical)Major depressive episodePsychiatric Status Rating ScalesPharmacologyDepressive Disorderbusiness.industryMiddle AgedOxindolesProlactinchemistryDopamine receptorAnesthesiaDopamine AgonistsAutoreceptorAntidepressantFemaleNeurology (clinical)medicine.symptombusinessPsychologymedicine.drugPsychopharmacology
researchProduct

SPECT-Untersuchungen mit dem 123I-markierten Dopamintransporter-Liganden FP-CIT (DaTSCANTM)

2019

ZusammenfassungDie S1-Leitlinie soll bei der Indikationsstellung, Durchführung, Interpretation und Befundung von SPECT-Untersuchungen des Dopamintransporters (DAT) mit DaTSCANTM unterstützen. Gegenüber der Vorgängerversion von 2007 berücksichtigt die vorliegende Aktualisierung und Überarbeitung die neuere wissenschaftliche Literatur, zwischenzeitlich veröffentlichte Guidelines der europäischen (EANM) und amerikanischen Fachgesellschaften (SNM), sowie die aktuelle Fassung der S3-Leitlinie „Idiopathisches Parkinson-Syndrom“ der Deutschen Gesellschaft für Neurologie. Zudem finden neue technische Möglichkeiten Berücksichtigung.

medicine.medical_specialtybiologybusiness.industrymedicinebiology.proteinRadiology Nuclear Medicine and imagingMedical physicsGeneral MedicineGuidelinebusinessDopamine transporterNuklearmedizin
researchProduct

A comparative analysis of striatal and extrastriatal D2/D3 binding of five pharmacologically different “atypical” antipsychotics

2006

Neurologybusiness.industryCognitive NeuroscienceMedicinePharmacologybusinessNeuroImage
researchProduct

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.

2005

Positron emission tomography (PET) studies reveal that clozapine at clinically used doses occupies less than 60% of D2/D3 dopamine receptors in human striatum. Here, the occupancy of D2/D3 dopamine receptors by clozapine in patients with schizophrenia was determined to test the hypothesis that clozapine binds preferentially to extrastriatal dopamine receptors. A total of 15 clozapine-treated inpatients with schizophrenia underwent a [18F]fallypride PET scan. Receptor occupancy was calculated as percent reduction in binding potential relative to unblocked values measured in seven normal volunteers. Mean D2/D3 receptor occupancy was statistically significantly higher in cortical (inferior tem…

AdultMalemedicine.medical_specialtyPsychosisPyrrolidinesDopamineStriatumBinding CompetitiveReceptors DopamineDopamine receptor D3Internal medicinemedicineHumansClozapineClozapinePharmacologyTemporal cortexDose-Response Relationship DrugChemistryReceptors Dopamine D2PutamenReceptors Dopamine D3Middle Agedmedicine.diseaseCorpus StriatumTemporal LobePsychiatry and Mental healthEndocrinologyFallyprideDopamine receptorAnesthesiaPositron-Emission TomographyBenzamidesSchizophreniaFemalemedicine.drugAntipsychotic AgentsNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas

2010

Quetiapine is next to clozapine an antipsychotic agent that exerts hardly any extrapyramidal side-effects at clinical efficacious doses. Some previous receptor occupancy studies reported preferential extrastriatal D2/3 receptor (D2/3R)-binding properties of second-generation antipsychotics and suggested this as possible reason for improved tolerability. This positron emission tomography (PET) investigation was designed to compare the occupancy of dopamine D2/3Rs by quetiapine in striatal and extrastriatal brain regions. Therefore, a cohort of 16 quetiapine-treated psychotic patients underwent an [18F]fallypride (FP) PET scan. Due to the high affinity of FP and its comparatively long half-li…

AdultMaleDibenzothiazepinesPyrrolidinesCaudate nucleusPharmacologyBinding CompetitiveQuetiapine FumarateYoung AdultQuetiapine FumarateDopamine receptor D2HumansMedicinePharmacology (medical)ClozapineVisual CortexPharmacologyTemporal cortexReceptors Dopamine D2business.industryReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumTemporal LobePsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesSchizophreniaQuetiapineFemalebusinessAntipsychotic Agentsmedicine.drugThe International Journal of Neuropsychopharmacology
researchProduct

Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis

2021

Background: Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited. Aims: Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database. Methods: A large therapeutic drug monitoring dataset of clozapine plasma concentrations considering three patient subgroups was analysed: a control group (CLZ0, 20–30 kg/m2, n=266), a group with high body mass index (CLZhigh, body mass index ⩾30 kg/m2, n=162) and with low body mass index values (CLZlow, body mass index &lt;20 kg/m2, n=27). Comparisons of plasma and dose-adjusted plasma concentrations (C/D) of clozapine…

AdultMaleBiological AvailabilityPharmacologyBody weightBody Mass IndexYoung Adult03 medical and health sciencesSex Factors0302 clinical medicinePharmacokineticsmedicineHumansTissue DistributionPharmacology (medical)ObesityClozapineClozapineAgedRetrospective StudiesA determinantAged 80 and overPharmacologymedicine.diagnostic_testbusiness.industryBody WeightMiddle Agedmedicine.diseaseObesity030227 psychiatryPsychiatry and Mental healthAdipose TissueLiverTherapeutic drug monitoringPlasma concentrationFemaleDrug MonitoringbusinessBody mass index030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Psychopharmacology
researchProduct

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.

1996

A double-blind, randomized, parallel study in 167 hospitalized patients with major depression and melancholia was conducted to determine if rapidly escalated doses of venlafaxine produced an earlier response, compared with rapidly escalated doses of imipramine. The daily dose of venlafaxine was rapidly increased to 375 mg/day over a five-day period, was maintained at this level for 10 days, and then was reduced to 150 mg/day for the remainder of the study. The imipramine dose was rapidly increased to 200 mg/day over five days and was maintained at this level to the end of the study. The primary efficacy variables were time to response and time to sustained response on the HAM-D and MADRS. N…

AdultMaleImipraminePersonality Inventorymedicine.medical_treatmentVenlafaxineAntidepressive Agents TricyclicImipramineDrug Administration ScheduleDouble blindDouble-Blind MethodMelancholiamedicineHumansBiological PsychiatryDepression (differential diagnoses)Rapid responseChemotherapyDepressive DisorderDose-Response Relationship DrugVenlafaxine HydrochlorideParallel studyMiddle AgedCyclohexanolsPsychiatry and Mental healthTreatment OutcomeAnesthesiaAntidepressive Agents Second-GenerationFemalemedicine.symptomPsychologymedicine.drugJournal of psychiatric research
researchProduct

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidep…

2021

Contains fulltext : 238693.pdf (Publisher’s version ) (Open Access) Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic …

Drugmedicine.medical_specialtyprecision medicinetherapeutic drug monitoringmedia_common.quotation_subjectStress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13]brain imagingNeuroimagingPsykiatri03 medical and health sciences0302 clinical medicinePharmacotherapyNeuroimagingmedicineHumansIntensive care medicineBiological Psychiatrypharmacogeneticsmedia_commonPsychiatrymedicine.diagnostic_testbusiness.industryAntidepressantsPrecision medicineAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTherapeutic drug monitoringPharmacogeneticsAntidepressants; brain imaging; pharmacogenetics; precision medicine; therapeutic drug monitoring; Antidepressive Agents; Drug Monitoring; Humans; Neuroimaging; Pharmacogenetics; PsychiatryAntidepressants; brain imaging; precision medicine; pharmacogenetics; therapeutic drug monitoringDrug MonitoringbusinessPharmacogeneticsWorld Journal of Biological Psychiatry
researchProduct

Dopamine in amygdala gates limbic processing of aversive stimuli in humans

2008

Dopamine is known to contribute to the amygdala-mediated aversive response, where increased dopamine release can augment amygdala function. Combining fMRI and PET imaging techniques, Kienast et al. present findings that suggest a functional link between anxiety temperament, dopamine storage capacity and emotional processing in the amygdala. Dopamine is released under stress and modulates processing of aversive stimuli. We found that dopamine storage capacity in human amygdala, measured with 6-[18F]fluoro-L-DOPA positron emission tomography, was positively correlated with functional magnetic resonance imaging blood oxygen level–dependent signal changes in amygdala and dorsal anterior cingula…

AdultMaleFluorine RadioisotopesDopamineBrain mappingAmygdalaGyrus CinguliDopaminemedicineImage Processing Computer-AssistedLimbic SystemPsychophysicsHumansAnterior cingulate cortexSystems neuroscienceBrain Mappingmedicine.diagnostic_testGeneral NeuroscienceMiddle AgedAmygdalaMagnetic Resonance ImagingDihydroxyphenylalanineFunctional imagingOxygenAffectmedicine.anatomical_structurenervous systemPositron-Emission TomographyAversive StimulusFunctional magnetic resonance imagingPsychologyNeurosciencepsychological phenomena and processesmedicine.drug
researchProduct

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

2011

Background Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effect…

AgonistAdultMaleFluorine RadioisotopesPyrrolidinesmedicine.drug_classDopamineReceptors Opioid muPharmacologySeverity of Illness IndexRemifentanilRadioligand AssayDopamine receptor D1PiperidinesDopamine receptor D3DopaminemedicineLimbic SystemHumansBiological PsychiatryReceptors Dopamine D2PutamenFunctional NeuroimagingVentral striatumAlcohol dependenceMiddle AgedAnalgesics OpioidBehavior AddictiveAlcoholismmedicine.anatomical_structurenervous systemFallypridePositron-Emission TomographyBenzamidesPsychologymedicine.drugBiological psychiatry
researchProduct

PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity

2005

Conventional methods for the graphical analysis of 6-[18F]fluorodopa (FDOPA)/positron emission tomography (PET) recordings ( Kappin) may be prone to negative bias because of oversubtraction of the precursor pool in the region of interest, and because of diffusion of decarboxylated FDOPA metabolites from the brain. These effects may reduce the sensitivity of FDOPA/PET for the detection of age-related changes in dopamine innervations. To test for these biasing effects, we have used a constrained compartmental analysis to calculate the brain concentrations of the plasma metabolite 3- O-methyl-FDOPA (OMFD) during 120 mins of FDOPA circulation in healthy young, healthy elderly, and Parkinson's …

AdultAgingFluorine Radioisotopesmedicine.medical_specialtyMetaboliteDiffusionCentral nervous system diseasechemistry.chemical_compoundDopamineInternal medicinemedicineHumans18F-fluorodopamineFluorodopamedicine.diagnostic_testbusiness.industryPutamenBrainHuman brainMiddle Agedmedicine.diseaseDihydroxyphenylalanineEndocrinologymedicine.anatomical_structureNeurologychemistryPositron emission tomographyPositron-Emission TomographyNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessmedicine.drugJournal of Cerebral Blood Flow &amp; Metabolism
researchProduct

Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease

2010

Udgivelsesdato: 2010-Feb-15 PET studies with the DOPA decarboxylase substrate 6-[(18)F]fluoro-l-DOPA (FDOPA) reveal the storage of [(18)F]-fluorodopamine within synaptic vesicles, mainly of dopamine fibres. As such, FDOPA PET is a sensitive indicator of the integrity of the nigrostriatal dopamine innervation. Nonetheless, there have been several reports of focal elevations of FDOPA utilization in brain of patients with Parkinson's disease (PD), all based on reference tissue methods. To investigate this phenomenon further, we used voxel-wise steady-state kinetic analysis to search for regions of elevated FDOPA utilization (K; ml g(-1) min(-1)) and steady-state trapping (V(d); ml g(-1)) in a …

AdultMalemedicine.medical_specialtyParkinson's diseaseMetabolic Clearance RateCognitive NeuroscienceStriatumNucleus accumbensPeriaqueductal grayNucleus AccumbensDopamineInternal medicinemedicineHumansPeriaqueductal GrayAgedAromatic L-amino acid decarboxylasebusiness.industryParkinsonismPutamenParkinson DiseaseMiddle Agedmedicine.diseaseDihydroxyphenylalanineEndocrinologyNeurologyPositron-Emission TomographyFemaleRadiopharmaceuticalsbusinessNeurosciencemedicine.drugNeuroImage
researchProduct

Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge

2005

Summary Objective To verify findings of an independently regulated anterior limbic alpha band source. Methods In a randomised cross-over study, the spontaneous EEG was recorded in nine healthy subjects after i.v. lorazepam or placebo. Intracerebral current densities within classical frequency bands were estimated with low resolution electromagnetic tomography [LORETA] and compared between groups with t -statistical parametric mapping [SPM{ t }]. A region-of-interest [ROI] based method was used to compare frontal and occipital alpha band activity changes. Results Irrespective of treatment group, local maxima of alpha band power were localised both in the occipital lobe, Brodman area [BA] 18,…

AdultMaleCingulate cortexFrequency bandAlpha (ethology)ElectroencephalographyLorazepamStatistical parametric mappingStatistics NonparametricElectromagnetic FieldsNuclear magnetic resonanceLimbic systemPhysiology (medical)mental disordersLimbic SystemmedicineHumansSingle-Blind MethodAnterior cingulate cortexPhysicsCross-Over Studiesmedicine.diagnostic_testSensory SystemsAlpha Rhythmmedicine.anatomical_structureNeurologyInjections IntravenousNeurology (clinical)Occipital lobeNeuroscienceClinical Neurophysiology
researchProduct

10 How valid are therapeutic reference ranges for psychotropic drugs?

2020

Pharmacopsychiatry
researchProduct

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

2000

Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.

AdultMalemedicine.medical_specialtyPsychosismedicine.medical_treatmentSigma receptorPanamesineDrug Administration ScheduleBasal Ganglia DiseasesPiperidinesInternal medicinemental disordersmedicineHumansReceptors sigmaAntipsychoticOxazolesBiological PsychiatryBiotransformationAgedPsychiatric Status Rating ScalesDose-Response Relationship DrugMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthEndocrinologyTreatment OutcomeTolerabilityDopamine receptorSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychiatry research
researchProduct

Functional polymorphism in the neuropeptide Y gene promoter (rs16147) is associated with serum leptin levels and waist-hip ratio in women

2013

&lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; The neuropeptide-Y (NP-Y) gene is a strong candidate gene in the pathophysiology of obesity-linked behavior, and several single-nucleotide polymorphisms of NP-Y have already been linked to body weight and appetite. However, the results from current studies remain inconclusive. The aim of the present study was to test whether a certain functional genetic variant (SNP rs16147) in the NP-Y promoter gene is associated with serum leptin levels and body fat distribution. &lt;b&gt;&lt;i&gt;Method:&lt;/i&gt;&lt;/b&gt; We genotyped and measured the serum leptin levels of the NP-Y rs16147 polymorphism in 1,097 Caucasian subjects in the context of a pop…

AdultMaleLeptinCandidate genemedicine.medical_specialtyGenotypeblood [Leptin]Medicine (miscellaneous)610 Medicine & healthmacromolecular substancesPolymorphism Single NucleotideWhite PeopleStatistics NonparametricWaist–hip ratiogenetics [Obesity]Sex FactorsMedizinische FakultätInternal medicineGenotypemedicineHumansNeuropeptide YObesityddc:610Genephysiology [Neuropeptide Y]Nutrition and Dieteticsbusiness.industryWaist-Hip RatioLeptinCase-control study2701 Medicine (miscellaneous)Middle AgedNeuropeptide Y receptormedicine.diseaseObesitygenetics [European Continental Ancestry Group]EndocrinologyCase-Control Studies10054 Clinic for Psychiatry Psychotherapy and Psychosomatics2916 Nutrition and DieteticsFemalegenetics [Neuropeptide Y]businessphysiology [Polymorphism Single Nucleotide]
researchProduct

Replication of the association between CHRNA4 rs1044396 and harm avoidance in a large population-based sample.

2015

Harm avoidance is a personality trait characterized by excessive worrying and fear of uncertainty, which has repeatedly been related to anxiety disorders. Converging lines of research in rodents and humans point towards an involvement of the nicotinic cholinergic system in the modulation of anxiety. Most notably, the rs1044396 polymorphism in the CHRNA4 gene, which codes for the α4 subunit of the nicotinic acetylcholine receptor, has been linked to negative emotionality traits including harm avoidance in a recent study. Against this background, we investigated the association between harm avoidance and the rs1044396 polymorphism using data from N=1673 healthy subjects, which were collected …

genetics [Receptors Nicotinic]0301 basic medicineAdultMalemedicine.medical_specialtymedia_common.quotation_subjectContext (language use)Receptors NicotinicPolymorphism Single NucleotideNicotine03 medical and health sciences0302 clinical medicineHarm ReductionGermanymedicinePersonalityHumansPharmacology (medical)ddc:610PsychiatryBiological PsychiatryGenetic Association Studiesmedia_commonPharmacologybusiness.industrySmokinggenetics [Smoking]medicine.diseasePsychiatry and Mental healthNicotinic acetylcholine receptor030104 developmental biologyNicotinic agonistNeurologygenetics [Personality]AnxietyHarm avoidanceCholinergicFemaleNeurology (clinical)medicine.symptombusinessnicotinic acetylcholine receptor alpha4 subunit030217 neurology & neurosurgerymedicine.drugPersonalityEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system

2016

Investigations on the acute effects of alcohol in the human mesolimbic dopamine D2 /D3 receptor system have yielded conflicting results. With respect to the effects of alcohol on extrastriatal D2 /D3 dopamine receptors no investigations have been reported yet. Therefore we applied PET imaging using the postsynaptic dopamine D2 /D3 receptor ligand [18 F]fallypride addressing the question, whether intravenously applied alcohol stimulates the extrastriatal and striatal dopamine system. We measured subjective effects of alcohol and made correlation analyses with the striatal and extrastriatal D2 /D3 binding potential. Twenty-four healthy male μ-opioid receptor (OPRM1)118G allele carriers underw…

0301 basic medicinePharmacologymedicine.medical_specialtyMedicine (miscellaneous)D3 dopamine receptor binding03 medical and health sciencesPsychiatry and Mental health030104 developmental biology0302 clinical medicineEndocrinologyFallyprideDopamine receptorDopamine receptor D3DopamineInternal medicineDopamine receptor D2medicineOrbitofrontal cortexPsychologyPrefrontal cortexNeuroscience030217 neurology & neurosurgerymedicine.drugAddiction Biology
researchProduct

Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge.

2007

Previous studies suggested altered sensitivity of the GABA/benzodiazepine receptor system in alcoholic patients. Expanding on these findings, the present functional magnetic resonance imaging (fMRI) study aimed to assess whether a differential modulation of cognitive brain activation by an acute GABAergic drug challenge could be detected in patients with alcoholism. Eight detoxified male patients meeting DSM-IV criteria for alcohol dependence and nine healthy male control subjects were studied with fMRI while performing a 2-back working memory task. The fMRI scans were performed 1 h after intravenous administration of saline and again 1 h after 0.03 mg/kg lorazepam I.V. After saline, a task…

AdultMaleCerebellummedicine.medical_specialtyPsychometricsmedicine.drug_classNeuroscience (miscellaneous)Prefrontal CortexLorazepamDrug Administration ScheduleInternal medicineCerebellummedicineHumansRadiology Nuclear Medicine and imagingGABA ModulatorsBenzodiazepineMemory Disordersmedicine.diagnostic_testWorking memoryAlcohol dependenceLorazepamReceptors GABA-AMagnetic Resonance ImagingFunctional imagingPsychiatry and Mental healthAlcoholismmedicine.anatomical_structureEndocrinologySedativePsychologyFunctional magnetic resonance imagingCognition DisordersNeuroscienceChlormethiazolemedicine.drugPsychiatry research
researchProduct

Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability.

2012

Previous positron emission tomography (PET) studies employing competition paradigms have shown either no change or substantial declines in striatal ( 11 C)-raclopride binding after challenge with psychotogenic doses of the N-methyl-D-aspartate antagonist ketamine. We sought to probe the relationship between the severity of ketamine-induced psychotic symptoms and altered dopamine D2/3 receptor availability throughout brain using the high affinity ligand ( 18 F)-fallypride (FP). PET recordings were obtained in a group of 10 healthy, young male volunteers, in a placebo condition, and in the course of an infusion with ketamine at a psychotomimetic dose. Administration of the Positive and Negati…

AdultMalemedicine.medical_specialtyPsychosisCaudate nucleusContext (language use)Genetics BehavioralYoung AdultInternal medicinemedicineHumansPharmacology (medical)Single-Blind MethodPharmacologyRaclopridePositive and Negative Syndrome ScaleReceptors Dopamine D2Receptors Dopamine D3Psychotomimeticmedicine.diseaseUp-RegulationPsychiatry and Mental healthEndocrinologyFallyprideSchizophreniaAnesthesiaPositron-Emission TomographyBenzamidesKetaminePsychologymedicine.drugProtein BindingThe international journal of neuropsychopharmacology
researchProduct

Opioid receptor PET reveals the psychobiologic correlates of reward processing.

2008

Little is known about the neurobiologic correlates of human personality. On the basis of the key role of the central opioidergic system in addiction and substance abuse, we investigated the relationship between certain personality traits that are supposed to be relevant in addiction and the opioid receptor status in healthy subjects.We investigated 23 healthy male volunteers who were extensively clinically tested to exclude substance abuse. All of the subjects underwent 1 PET scan with the subtype-nonselective opioidergic radioligand 18F-fluoroethyl-diprenorphine under resting conditions without sensory or cognitive stimulation. Subsequently, the subjects were psychologically tested for the…

AdultMalemedicine.medical_specialtyFluorine Radioisotopesmedicine.drug_classmedia_common.quotation_subjectDiprenorphineBasal GangliaNucleus AccumbensRewardOpioid receptormedicinePersonalityHumansRadiology Nuclear Medicine and imagingPsychiatryRadionuclide Imagingmedia_commonOpioidergicBrain Mappingbusiness.industryAddictionNovelty seekingBrainMiddle Agedmedicine.diseaseSubstance abuseReward dependenceReceptors OpioidHarm avoidanceCaudate NucleusRadiopharmaceuticalsbusinessClinical psychologyPersonalityJournal of nuclear medicine : official publication, Society of Nuclear Medicine
researchProduct

The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients

1995

Roxindole is a potent autoreceptor-selective dopamine agonist with additional properties as a serotonin reuptake inhibitor and 5-HT1A agonist. In order to get more insight into its mode of action in various psychiatric populations, we evaluated the effects of subchronic roxindole treatment on pituitary and adrenal hormone secretion, i.e. release of prolactin, thyroid stimulating hormone (TSH), growth hormone (GH), luteinizing hormone (LH), and cortisol. Fifteen schizophrenic patients with positive and negative symptomatology, respectively, were treated with roxindole for 28 days. Both basal and thyrotropin releasing hormone (TRH) -induced prolactin secretion diminished significantly to 26.4…

AdultMaleendocrine systemmedicine.medical_specialtyIndolesHydrocortisoneendocrine system diseasesPyridinesThyrotropinThyrotropin-releasing hormonePharmacologyDopamine agonistchemistry.chemical_compoundThyroid-stimulating hormoneAnterior pituitaryRoxindoleInternal medicinemedicineHumansPharmacologybusiness.industryLuteinizing HormoneMiddle AgedProlactinGrowth hormone secretionOxindolesProlactinEndocrinologymedicine.anatomical_structurechemistryGrowth HormoneDopamine AgonistsSchizophreniaFemaleSchizophrenic PsychologyLuteinizing hormonebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugPsychopharmacology
researchProduct

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclo…

2008

To elucidate the Batypicality( of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. ( 18 F)fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Binding potentials were calculated for striatal and extrastriatal regions. D2/D3-receptor occupancies were expressed relative to binding potentials in 8 unmedicated patients. In a parallel ( 11 C)raclopride-PET stu…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesPyrrolidinesTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyBinding CompetitiveBasal GangliaPiperazinesYoung AdultDopamine receptor D3Internal medicinemedicineHaloperidolHumansPharmacology (medical)ZiprasidoneCarbon RadioisotopesTemporal cortexRacloprideDose-Response Relationship DrugChemistryReceptors Dopamine D2Dopamine antagonistReceptors Dopamine D3Psychiatry and Mental healthThiazolesEndocrinologyFallyprideRaclopridePositron-Emission TomographyBenzamidesSchizophreniaDopamine AntagonistsFemaleRadiopharmaceuticalsmedicine.drugAntipsychotic AgentsJournal of clinical psychopharmacology
researchProduct

The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations

2011

The high-affinity radioligand [18F]fallypride (FP) is frequently used for quantification of striatal/extrastriatal D2/3 receptors and the receptor occupancies of antipsychotics (APs). Its 110 minutes half-life allows long scan durations. However, the optimum scan duration is a matter of debate. This investigation focuses on scan-duration-related effects on simplified reference tissue model (SRTM) results and the time point of transient equilibrium in a large sample of dynamic FP positron emission tomography (PET) scans. Fifty drug-free and 50 AP-treated subjects underwent FP-PET scans (180 minutes scan duration). The binding potential ( BPND) of the putamen, thalamus, and temporal cortex w…

AdultMalePyrrolidinesTime FactorsMaterials scienceAdolescentShuttle Radar Topography MissionRadioligand AssayYoung AdultRadioligandmedicineHumansTemporal cortexTransient equilibriummedicine.diagnostic_testReceptors Dopamine D2business.industryMental DisordersPutamenReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumNeurologyFallypridePositron emission tomographyPositron-Emission TomographyBenzamidesFemaleOriginal ArticleNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessAntipsychotic AgentsJournal of Cerebral Blood Flow &amp; Metabolism
researchProduct

Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Me…

2019

Background Impaired subjective well-being in schizophrenia patients treated with antipsychotics has often been linked inter alia to the antidopaminergic effects of medication. Thus, it is important to capture the association between striatal dopamine D2 receptor occupancy (D2-RO) and global subjective well-being. We examined this association using data from our multicenter, randomized, double-blind Neuroleptic Strategy Study (NeSSy). Methods An innovative double randomization process was used for allocation of patients to the specific treatment groups. Plasma drug concentrations were measured after 6 and 24 weeks of treatment to obtain the estimated D2-RO (eD2-RO) relative to literature val…

AdultMaleOlanzapinemedicine.medical_specialtymedicine.medical_treatmentAripiprazolePersonal SatisfactionMedication Adherencelaw.invention03 medical and health sciencesSex Factors0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHaloperidolHumansPharmacology (medical)AntipsychoticReceptors Dopamine D2business.industryMiddle Agedmedicine.disease3. Good health030227 psychiatryFlupentixolFlupenthixolDopamine D2 Receptor AntagonistsPsychiatry and Mental healthOlanzapineSchizophreniaQuality of LifeSchizophreniaHaloperidolQuetiapineFemaleSchizophrenic PsychologyAripiprazolebusiness030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression*

1992

Dopamine autoreceptor agonists reduce the firing rate, synthesis, and release of dopamine in dopaminergic neurons by means of a negative feedback mechanism via stimulation of autoreceptors. Moreover, dopamine autoreceptor agonists are able to stimulate supersensitive but not normosensitive postsynaptic receptors. For dopamine autoreceptor agonists, therapeutic effects by readjustment of excessive or deficient dopaminergic function have been postulated for positive and negative schizophrenic symptomatology as well as for subtypes of depressive disorders. Investigations on the therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia or depression have yielded incons…

Depressive Disordermedicine.medical_specialtyDopamine AgentsDopaminergicGeneral MedicineDopamine agonistTalipexolePsychiatry and Mental healthchemistry.chemical_compoundEndocrinologyRoxindolechemistryDopamine receptorDopamine receptor D3DopamineInternal medicineSchizophreniamedicineAutoreceptorAnimalsHumansPharmacology (medical)PsychiatryPsychologymedicine.drugPharmacopsychiatry
researchProduct

[ 18 F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors

2001

5-(2'-[18F]Fluoroethyl)flumazenil ([18F]FEF) is a fluorine-18 labelled positron emission tomography (PET) tracer for central benzodiazepine receptors. Compared with the established [11C]flumazenil, it has the advantage of the longer half-life of the fluorine-18 label. After optimisation of its synthesis and determination of its in vitro receptor affinities, we performed first PET studies in humans. PET studies in seven healthy human volunteers were performed on a Siemens ECAT EXACT whole-body scanner after injection of 100-280 MBq [L8F]FEF. In two subjects, a second PET scan was conducted after pretreatment with unlabelled flumazenil (1 mg or 2.5 mg i.v., 3 min before tracer injection). A t…

FlumazenilMalemedicine.drug_classNuclear magnetic resonancemedicineHumansRadiology Nuclear Medicine and imagingReceptorTemporal cortexBenzodiazepineChemistrybusiness.industryGABAA receptorBrainHalf-lifeBinding potentialGeneral MedicineHuman brainReceptors GABA-Amedicine.anatomical_structureFlumazenilRadiopharmaceuticalsNuclear medicinebusinessTomography Emission-Computedmedicine.drugEuropean Journal of Nuclear Medicine and Molecular Imaging
researchProduct

Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels

2002

In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. After completing 6 weeks of medication with either amisulpride or flupenthixol, the patients entered a long-term maintenance treatment with amisulpride 200–600 mg/day or flupenthixol 5–15 mg/day for a maximum of 12 months with a subsequent drug-free follow-up until month 15. Eighteen initially included patients were still participating in the study at month 6. In the flupenthixol group, only 1 patient treated reached month 12, and none of t…

AdultMalemedicine.medical_specialtyTime FactorsThyrotropin-releasing hormoneFlupenthixolDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansAmisulprideBenzamideThyrotropin-Releasing HormoneBiological PsychiatryMiddle AgedProlactinProlactinFlupentixolFlupenthixolPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologychemistrySchizophreniaFemaleAmisulprideSulpiridePsychologyAntipsychotic Agentsmedicine.drugHormoneNeuropsychobiology
researchProduct

Die nächste Generation „atypischer” Antipsychotika: Der Beitrag der Positronenemissionstomographie

2003

Almost fifteen years of research with Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have led to a profound understanding of the relationships between antipsychotic doses and plasma levels on the one hand and occupancy of (striatal) D 2 -like dopamine receptors on the other hand as well as with the associated clinical effects and side effects. Furthermore, with the development of clinically atypical" antipsychotics PET studies helped to generate hypotheses regarding the essential pharmacological properties of this heterogeneous class of drugs. Possible mechanisms of action include combined D 2 -/5-HT 2 antagonism, preferential mesolimbic binding, a…

Agonistmedicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classmedicine.medical_treatmentSingle-photon emission computed tomographyPsychiatry and Mental healthEndocrinologyNeurologyMechanism of actionPositron emission tomographyDopamine receptorIn vivoInternal medicinemedicineAripiprazoleNeurology (clinical)medicine.symptomPsychologyAntipsychoticmedicine.drugFortschritte der Neurologie · Psychiatrie
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct

Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Posit…

1997

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours …

AdultMaleTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyPiperidinesOral administrationmedicineHumansReceptor Serotonin 5-HT2ACarbon RadioisotopesPositron emissionDosing5-HT receptorPharmacologymedicine.diagnostic_testbusiness.industry5-HT2 receptorBrainHuman brainFluorobenzenesPsychiatry and Mental healthmedicine.anatomical_structureSpiperonePositron emission tomographyReceptors SerotoninFemaleSerotonin AntagonistsbusinessAntipsychotic AgentsTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?

1997

The purpose of this article is to compare and contrast the benefits and limitations of antidepressant drugs. Several different classes of antidepressants are available for treatment of major depressive disorder, each with its own benefits and limitations as a result of its pharmacological profile. Tricyclic antidepressants (TCAs) and monoamine oxidase (MAO) inhibitors are effective in a large proportion of depressed patients, but their use is often limited by short- and long-term safety/tolerability problems. Selective serotonin reuptake inhibitors (SSRIs) exhibit comparable efficacy to TCAs in most patients, but may be less effective in certain patients. Additionally, SSRI use may by impac…

chemistry.chemical_classificationbusiness.industryVenlafaxinePharmacologymedicine.diseasePsychiatry and Mental healthNeurologychemistryTolerabilitymedicineAntidepressantMajor depressive disorderAnxietyPharmacology (medical)Neurology (clinical)Onset of actionmedicine.symptomReuptake inhibitorbusinessTricyclicmedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age

2007

Molecular and functional imaging techniques reveal evidence for lateralization of human cerebral function. Based on animal data, we hypothesized that asymmetry in dopamine neurotransmission declines during normal aging. In order to test this hypothesis, we measured dopamine D2/3 receptor availability with [18F]desmethoxyfallypride-PET (DMFP) in putamen and caudate nucleus (NC) of 21 healthy, right-handed males (24-60 years; 35+/-10). For volumetric analysis, high-resolution T1-weighted MR-images were obtained in 18 of the PET-subjects in order to assess possible age-related decreases in NC and putamen volume. The calculated DMFP binding potentials (BP) showed a right-ward asymmetry in NC of…

AdultMaleAgingmedicine.medical_specialtyCognitive NeuroscienceCaudate nucleusNeurotransmissionFunctional LateralityLateralization of brain functionAnimal dataDopamineDopamine receptor D2Internal medicineSalicylamidesmedicineHumansTissue DistributionReceptors Dopamine D2PutamenReceptors Dopamine D3Middle AgedEndocrinologyNeurologyDopamine receptorPositron-Emission TomographyCaudate NucleusRadiopharmaceuticalsPsychologyNeurosciencemedicine.drugNeuroImage
researchProduct

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D …

1998

The benzamide amisulpride (ASP) is a selective D2-like dopamine antagonist, while flupentixol (FPX), a thioxanthene, blocks D2-like, D1-like and 5-HT2 receptors. To evaluate efficacy and safety of ASP and to investigate the importance of an additional D1-like antagonism for antipsychotic effects and extrapyramidal tolerability, a randomized double-blind multi-center study versus FPX as reference drug was performed for 6 weeks in 132 patients suffering from acute schizophrenia (DSM-III-R) with predominant positive symptomatology. Doses were initially fixed (ASP: 1000 mg/day; FPX: 25 mg/day) but could be reduced by 40% in case of side effects (mean daily doses: ASP: 956 mg; FPX: 22.6 mg). Int…

Pharmacologymedicine.medical_treatmentAntagonistDopamine antagonistPharmacologyFlupentixolBarnes Akathisia ScaleTolerabilitymedicineAmisulprideAntipsychoticAdverse effectPsychologymedicine.drugPsychopharmacology
researchProduct

The German multi-centre study on smoking-related behavior-description of a population-based case-control study

2011

Tobacco smoking is a major risk factor for most of the diseases leading in mortality. Nicotine dependence (ND), which sustains regular smoking, is now acknowledged to be under substantial genetic control with some environmental contribution. At present, however, genetic studies on ND are mostly conducted in populations that have been poorly characterized with regard to ND-related phenotypes for the simple reason that the respective populations were not primarily collected to study ND. The German multi-centre study 'Genetics of Nicotine Dependence and Neurobiological Phenotypes', which is funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) as part of the Priority …

Pharmacologyeducation.field_of_studymedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectPopulationCase-control studyMedicine (miscellaneous)Social environmentlanguage.human_languageGermanPsychiatry and Mental healthlanguageMedicinePersonalityRisk factoreducationbusinessRisk assessmentPsychiatryPsychosocialmedia_commonDemographyAddiction Biology
researchProduct

Welche Eigenschaften machen ein Neuroleptikum "atypisch"?

2001

Die Gruppe der “atypischen” Neuroleptika ist keine einheitliche Substanzklasse, sondern sowohl nach pharmakologischen als auch nach klinischen Kriterien sehr heterogen. Die Ubergange von dem prototypischen “atypischen” Neuroleptikum Clozapin zu den “konventionellen” Neuroleptika erscheinen fliesend. Anhand der praklinischen Besonderheiten dieser Substanzen und ihrer Charakteristika in SPECT- und PET-Studien werden die wesentlichen Konzepte diskutiert, die man heute fur die “Atypie” eines Neuroleptikums verantwortlich macht. Dazu zahlen insbesondere der kombinierte Antagonismus von D2-artigen Dopamin- und 5-HT2-Serotoninrezeptoren und die praferentielle Beeinflussung mesolimbischer dopaminer…

GynecologyPsychiatry and Mental healthmedicine.medical_specialtyNeurologyPositronen emissions tomographiebusiness.industryMedicineNeurology (clinical)General MedicinebusinessDer Nervenarzt
researchProduct

Neuroendocrine response to antipsychotics: effects of drug type and gender

1999

Abstract Background: To study the influences of drug type and gender on the neuroendocrine response to neuroleptic treatment, we compared the endocrine actions of two neuroleptics with different receptor affinity profiles—a substituted benzamide, amisulpride, a selective D 2 -like dopamine antagonist; and a thioxanthene, flupenthixol, a mixed D 1 /D 2 -like antagonist also blocking serotonin, H 1 , and D 1 receptors—on anterior pituitary hormone secretion in schizophrenic patients (DSM-III-R). Methods: Blood was withdrawn at 15-min intervals to assess basal secretion of prolactin, growth hormone (GH), and thyroid-stimulating hormone (TSH). Four hundred micrograms of thyrotropin-releasing ho…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesThyrotropinThyrotropin-releasing hormoneFlupenthixolPharmacologySex FactorsDouble-Blind MethodAnterior pituitaryThyroid-stimulating hormoneInternal medicinemedicineHumansAmisulprideBiological PsychiatryHuman Growth Hormonebusiness.industryDopamine antagonistNeurosecretory SystemsProlactinProlactinFlupenthixolmedicine.anatomical_structureEndocrinologySchizophreniaFemaleSchizophrenic PsychologyAmisulprideSulpiridebusinesshormones hormone substitutes and hormone antagonistsAntipsychotic Agentsmedicine.drugHormoneBiological Psychiatry
researchProduct

Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy

2009

Evidence has been given that antipsychotic effects of dopamine receptor antagonists are associated with 60 and 80% striatal dopamine D2 and D3 receptor occupancy. Receptor occupancy correlates well with concentrations of the antipsychotic drugs in serum or plasma, much better than the dose. The latter is consistent with weak correlations between antipsychotic dose and serum concentrations and explained by the high interindividual variabilities in drug metabolism. Using positron emission tomography (PET) for in vivo determination of dopamine receptor occupancy in conjunction with drug concentration measurements “therapeutic windows” could be calculated for the atypical antipsychotic drugs am…

medicine.diagnostic_testbusiness.industrymedicine.drug_classAtypical antipsychoticPharmacologyPsychiatry and Mental healthDopamine receptorDopamine receptor D3Therapeutic drug monitoringAnesthesiaMedicineZiprasidoneAripiprazoleAmisulpridebusinessClozapinemedicine.drugEuropean Psychiatry
researchProduct

Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.

2006

In animal studies, acute antipsychotic treatment was shown to enhance striatal DOPA-decarboxylase (DDC) activity. However, this phenomenon has not been demonstrated in humans by positron emission tomography (PET). Therefore, we investigated acute haloperidol effects on DDC activity in humans using [18F]fluorodopa (FDOPA) PET. Nine healthy volunteers were scanned with FDOPA in drug-free baseline conditions and after 3 days of haloperidol treatment (5 mg/day). A continuous performance test (CPT) was administered in both conditions. The net blood-brain clearance of FDOPA (K(in)app) in striatum, mesencephalon, and medial prefrontal cortex was calculated by volume-of-interest analysis. The macro…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesCognitive NeurosciencePrefrontal CortexStimulationStriatumNeuropsychological TestsMesencephalonInternal medicineBasal gangliamedicineHaloperidolImage Processing Computer-AssistedHumansAttentionFluorodopaPrefrontal cortexDominance Cerebralmedicine.diagnostic_testbusiness.industryPutamenBrainMiddle AgedCorpus StriatumDihydroxyphenylalanineEndocrinologyNeurologyPattern Recognition VisualPositron emission tomographyBlood-Brain BarrierPositron-Emission TomographyHaloperidolNuclear medicinebusinessPsychomotor Performancemedicine.drugNeuroImage
researchProduct

Medikamente zur Behandlung von Persönlichkeitsstörungen

1998

Die Therapie von Personlichkeitsstorungen war lange Zeit ausschlieslich eine Domane psychotherapeutischer Interventionen. Mittlerweile existieren einige kontrollierte Studien auch zum Einsatz von Psychopharmaka bei Personlichkeitsstorungen Die Ergebnisse sind aber fur allgemeine Empfehlungen noch zu wenig abgesichert. Die Diagnose von Personlichkeitsstorungen (z. B. Achse-Il-Storungen nach DSM-IV) ist fehleranfallig. Die diagnostischen Kategorien sind uneinheitlich und derzeit noch im Flus; selbst strukturierte Interviews erfahrener Untersucher zeigen nur begrenzte Verlaslichkeit. Wichtig ist die Erfassung und — wenn moglich — Abgrenzung von gleichzeitig vorhandenen Achse-I-Storungen nach D…

researchProduct

Impaired sleep quality and sleep duration in smokers-results from the German Multicenter Study on Nicotine Dependence

2012

Cigarette smoking is a severe health burden being related to a number of chronic diseases. Frequently, smokers report about sleep problems. Sleep disturbance, in turn, has been demonstrated to be involved in the pathophysiology of several disorders related to smoking and may be relevant for the pathophysiology of nicotine dependence. Therefore, determining the frequency of sleep disturbance in otherwise healthy smokers and its association with degree of nicotine dependence is highly relevant. In a population-based case-control study, 1071 smokers and 1243 non- smokers without lifetime Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Axis I disorder were investigated. S…

medicine.medical_specialtyPopulationMedicine (miscellaneous)Poison controlSleep Wake DisordersPittsburgh Sleep Quality Index03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineRisk factoreducationPsychiatryPharmacologyeducation.field_of_studySleep disorderbusiness.industrymedicine.diseaseSleep in non-human animals3. Good healthPsychiatry and Mental healthAnxietymedicine.symptombusiness030217 neurology & neurosurgeryAddiction Biology
researchProduct

Therapeutic monitoring of new antipsychotic drugs.

2004

Typical antipsychotic drugs qualify for therapeutic drug monitoring (TDM) primarily for the following reasons: control of compliance and avoidance of extrapyramidal side effects by keeping chronic exposure to minimal effective blood levels. For the atypical antipsychotic clozapine, drug safety is another reason to use TDM. With regard to the new antipsychotics risperidone, olanzapine, quetiapine, amisulpride, ziprasidone, and aripiprazole, which have been introduced in the clinic during the last few years, the rationale to use TDM is a matter of debate. Positron emission tomography (PET), which enables measurement of the occupancy of dopamine D2 receptors, revealed that receptor occupancy c…

PharmacologyOlanzapinemedicine.diagnostic_testDose-Response Relationship Drugmedicine.drug_classbusiness.industryReceptors Dopamine D2medicine.medical_treatmentAtypical antipsychoticPharmacologyTypical antipsychoticStructure-Activity RelationshipTherapeutic drug monitoringmedicineQuetiapineHumansPharmacology (medical)ZiprasidoneAmisulprideDrug MonitoringAntipsychoticbusinessmedicine.drugAntipsychotic AgentsTherapeutic drug monitoring
researchProduct

Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt

2009

Duloxetine is a potent and selective inhibitor of serotonin and norepinephrine reuptake with weak activity on dopamine reuptake (Wong et al. 1993). Daily doses of 60 mg are effective in the acute treatment of major depression. Duloxetine is extensively metabolized by cytochrome P450 isoenzymes (CYP) 1A2 and to a lesser extent 2D6 (Lobo et al. 2008) to numerous non-active metabolites. Maximum plasma concentration occurs after 6 h, steady-state within 3 d and the mean terminal half-life is 12 h. Fatal outcomes have been reported for acute overdoses as low as 1000 mg, and symptoms of duloxetine overdose are well described. However, information about plasma levels of duloxetine and correspondin…

Pharmacologybusiness.industryDuloxetine HydrochloridePharmacologyReuptakePsychiatry and Mental healthchemistry.chemical_compoundCerebrospinal fluidchemistryDopaminemedicineCerebrospinal fluid penetrationDuloxetinePharmacology (medical)SerotoninbusinessDepression (differential diagnoses)medicine.drugThe International Journal of Neuropsychopharmacology
researchProduct

High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.

2003

The 'atypicality' of the antipsychotic drug, amisulpride, has been attributed to preferential extrastriatal binding. Previous investigations of striatal D2 receptor occupancy by amisulpride revealed conflicting results. The aim of this PET study was to measure the striatal occupancy by amisulpride and to correlate it with the corresponding drug plasma concentrations. Nine amisulpride-treated patients and 12 healthy volunteers serving as controls were studied with PET and [18F]desmethoxyfallypride. Occupancy values and plasma concentrations were nonlinearly fitted to an E max model. Results showed 43-85% (putamen) and 67-90% (caudate) D2-like receptor occupancy. Plasma amisulpride concentrat…

AdultMaleOccupancyPharmacologyDopamine receptor D2Image Interpretation Computer-AssistedSalicylamidesmedicineHumansPharmacology (medical)AmisulprideReceptorPharmacologyCerebral CortexChemistryReceptors Dopamine D2PutamenDesmethoxyfallypridePutamenMiddle Agedmedicine.diseaseNeostriatumPsychiatry and Mental healthSchizophreniaDopamine receptorArea Under CurvePositron-Emission TomographySchizophreniaFemaleAmisulprideCaudate NucleusRadiopharmaceuticalsSulpirideAlgorithmsmedicine.drugAntipsychotic AgentsThe international journal of neuropsychopharmacology
researchProduct

P50 sensory gating and smoking in the general population

2011

P50 gating is a major functional biomarker in research on schizophrenia and other psychiatric conditions with high smoking prevalence. It is used as endophenotype for studying nicotinic systems genetics and as surrogate endpoint measure for drug development of nicotinic agonists. Surprisingly, little is known about P50 gating in the general population and the relationship to smoking-related characteristics. In this multicenter study at six academic institutions throughout Germany, n = 907 never-smokers (NS < 20 cigarettes/lifetime), n = 463 light smokers (LS) with Fagerstrom Test for Nicotine Dependence (FTND) ≥ 4 and n = 353 heavy smokers (HS, FTND < 4) were randomly selected from the gene…

PharmacologyFagerstrom Test for Nicotine Dependenceeducation.field_of_studymedicine.medical_specialtySensory gatingPopulationMedicine (miscellaneous)GatingAudiologymedicine.diseaseBrain mappingFunctional imagingPsychiatry and Mental healthmedicine.anatomical_structureSchizophreniaEndophenotypemedicineeducationPsychologyNeuroscienceAddiction Biology
researchProduct

Medikamente zur Phasenprophylaxe affektiver Psychosen und zur Behandlung manischer Syndrome

1998

Folgende Substanzgruppen sind in der Therapie manischer Syndrome und/oder in der Phasenprophylaxe affektiver Storungen etabliert (Im folgenden werden die Begriffe affektive bzw. schizoaffektive „Storung“ bzw. „Psychose“ weitgehend synonym verwendet.)

researchProduct

Acute Alcohol Effects on Neuronal and Attentional Processing: Striatal Reward System and Inhibitory Sensory Interactions under Acute Ethanol Challenge

2004

The acute influence of ethanol on cerebral activity induces complex psycho-physiological effects that are considerably more pronounced during acute ethanol influx than during maximal blood alcohol concentration (elimination phase). Despite the psychiatric and forensic relevance of these different ethanol effects, the underlying neuronal mechanisms are still unclear. In total, 20 male healthy volunteers were investigated each with three different experimental conditions in a randomized order using an intravenous ethanol challenge (40 g bolus infusion): during influx phase, elimination phase, and under placebo condition. During and after the ethanol (or placebo) infusion, neuropsychological t…

AdultMaleCentral nervous systemSensory systemStriatumNeuropsychological TestsPlaceboRewardFluorodeoxyglucose F18Cortex (anatomy)Image Processing Computer-AssistedmedicineHumansAttentionSingle-Blind MethodSensory cortexBrain ChemistryNeuronsPharmacologyTemporal cortexEthanolCentral Nervous System DepressantsReciprocal inhibitionNeostriatumPsychiatry and Mental healthGlucosemedicine.anatomical_structurePsychologyNeuroscienceTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Lack of association of a functional catechol-O-methyltransferase gene polymorphism with risk of tobacco smoking: results from a multicenter case-cont…

2013

Background The catechol-O-methyltransferase (COMT) modulates dopaminergic neurotransmission in the prefrontal cortex as well as in the mesolimbic reward system. Since the reward system mediates addictive behavior, the COMT gene is a strong candidate gene regarding the pathophysiology of tobacco dependence and smoking behavior. Because of rather conflicting results in previous studies, the purpose of the present study was to test for association between a functional genetic variant in the COMT gene (single nucleotide polymorphism [SNP] rs4680) and tobacco smoking behavior. Methods In a population-based case-control multicenter study designed for tobacco addiction research, a total of 551 cur…

AdultCandidate genemedia_common.quotation_subjectPopulationEuropean Continental Ancestry Groupgenetics [Catechol O-Methyltransferase]Single-nucleotide polymorphism610 Medicine & healthCatechol O-MethyltransferasePolymorphism Single NucleotideWhite PeopleGermanymental disordersSNPMedicineHumanseducationmedia_commonGeneticseducation.field_of_studyCatechol-O-methyl transferasebusiness.industryAddictionSmokingPublic Health Environmental and Occupational Healthgenetics [Smoking]Tobacco Use Disorder2739 Public Health Environmental and Occupational HealthMiddle Agedmedicine.diseaseCase-Control Studies10054 Clinic for Psychiatry Psychotherapy and Psychosomaticsddc:640genetics [Tobacco Use Disorder]businessAddictive behaviorrs4680
researchProduct

Dopamine D2/D3 receptor availability and venturesomeness.

2011

The construct of impulsivity is considered as a major trait of personality. There is growing evidence that the mesolimbic dopamine system plays an important role in the modulation of impulsivity and venturesomeness, the two key components within the impulsivity-construct. The aim of the present study was to explore an association between trait impulsivity measured with self-assessment and the dopaminergic neurotransmission as measured by positron emission tomography (PET) in a cohort of healthy male subjects. In vivo D2/D3 receptor availability was determined with [(18)F]fallypride PET in 18 non-smoking healthy subjects. The character trait impulsivity was measured using the Impulsiveness-V…

AdultMaleSelf-AssessmentPyrrolidinesStatistics as TopicNeuroscience (miscellaneous)Neuropsychological TestsImpulsivityStatistical parametric mappingPersonality AssessmentBrain mappingDevelopmental psychologyCohort StudiesYoung AdultRisk-TakingDopamine receptor D3Dopamine receptor D2Surveys and QuestionnairesmedicineHumansRadiology Nuclear Medicine and imagingTemporal cortexBrain MappingReceptors Dopamine D2BrainPsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesImpulsive Behaviormedicine.symptomPersonality Assessment InventoryPsychologyNeurosciencePsychiatry research
researchProduct

Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic

1999

Rationale: EMD 57445 (panamesine) is a high affinity sigma ligand with the profile of an atypical antipsychotic in animal studies. It has been reported recently to have antipsychotic activity in schizophrenia. However, its metabolite, EMD 59983, binds also to D2 and D3 dopamine (DA) receptors. Objectives: The aim of this study was to test, using single photon emission computed tomography (SPECT) and [123I]iodobenzamide (IBZM) as the radiotracer, whether EMD 59983 would pass the blood-brain barrier and to what extent it would contribute to the effects of EMD 57445 in schizophrenia. Methods: Two IBZM SPECT-scans were performed in five neuroleptic-free schizophrenic patients (DSM IV), one befo…

AdultMalemedicine.medical_specialtyPyrrolidinesmedicine.drug_classmedicine.medical_treatmentSigma receptorAtypical antipsychoticPanamesinePharmacologychemistry.chemical_compoundIodobenzamidePiperidinesDopamine receptor D3DopamineInternal medicinemedicineHumansReceptors sigmaAntipsychoticOxazolesTomography Emission-Computed Single-PhotonPharmacologyReceptors Dopamine D2Middle AgedCorpus StriatumPyrimidinesEndocrinologychemistryBlood-Brain BarrierDopamine receptorBenzamidesSchizophreniaFemaleAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomog…

2007

The telencephalic dopamine innervations contribute to the modulation of cognitive processing. However, the relationship between cognitive effects of D(2/3)-receptor antagonism and dopamine transmission is not described in healthy subjects. We therefore tested effects of acute haloperidol (5 mg/d over 3 days) on continuous performance task (CPT) performance and 6-[(18)F]-fluoro-l-DOPA (FDOPA) PET parameters. Nine physically and mentally healthy male men performed two FDOPA-PET scans including arterial plasma withdrawal. Over 3 days before the second scan, all subjects were treated with 5 mg/d haloperidol orally. Using our novel steady-state analysis, we calculated the intrinsic rate of the c…

AdultMalemedicine.medical_specialtyCognitive NeuroscienceDopamineKineticsStriatumNeuropsychological TestsCognitionDopamineContinuous performance taskFluorodeoxyglucose F18Predictive Value of TestsInternal medicinemedicineHaloperidolImage Processing Computer-AssistedHumansEffects of sleep deprivation on cognitive performancePsychiatryBrain Chemistrymedicine.diagnostic_testHealthy subjectsReceptors Dopamine D3BrainMiddle AgedDopamine D2 Receptor AntagonistsEndocrinologyNeurologyPositron emission tomographyData Interpretation StatisticalPositron-Emission TomographyDopamine AntagonistsHaloperidolFemaleRadiopharmaceuticalsPsychologyAlgorithmsPsychomotor Performancemedicine.drugNeuroImage
researchProduct

In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine rece…

2007

Abstract Benzamide derivatives as radiotracers have played an important role in diagnosing malfunction in dopaminergic neurotransmission. A variety of halogenated and two unsubstituted benzamide derivatives were synthesised and their in vitro affinities to dopaminergic, serotonergic and adrenergic receptors and their lipophilicities were determined. As references IBZM (3), raclopride (4) and FLB457 (5) were tested as well. The two iodinated compounds NAE (27) and NADE (28) displayed Ki values of 0.68 and 14 nM for the D2 receptor. The well-established radiotracers FP (1) and DMFP (2) showed affinities in the same range as did the brominated compounds NABrE (29) and NABrDE (30). The log D7.4…

StereochemistryClinical BiochemistryPharmaceutical ScienceBiochemistryCell Linechemistry.chemical_compoundRadioligand AssayStructure-Activity RelationshipDopamine receptor D2Iodine IsotopesDrug DiscoverymedicineAnimalsBenzamideMolecular BiologyRacloprideReceptors Dopamine D2Organic ChemistryDopaminergicLigand (biochemistry)AffinitieschemistryDopamine receptorLipophilicityBenzamidesMolecular Medicinemedicine.drugBioorganicmedicinal chemistry
researchProduct

Corrigendum to “The thalamus as the generator and modulator of EEG alpha rhythm: A combined PET/EEG study with lorazepam challenge in humans” [NeuroI…

2006

Department of Psychiatry, Johannes Gutenberg–University Mainz, 55131 Mainz, GermanyAvailable online 2 May 20061053-8119/$ - see front matter D 2006 Elsevier Inc. All rights reserved.doi:10.1016/j.neuroimage.2006.03.007DOI of original article:10.1016/j.neuroimage.2004.01.047.* Corresponding author. Department of Nuclear Medicine, Johannes Gutenberg–University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. Fax: +496131 17 2448.E-mail address: schreckenberger@nuklear.klinik.uni-mainz.de (M. Schreckenberger).Available online on ScienceDirect (www.sciencedirect.com).

RhythmNeurologymedicine.diagnostic_testCognitive NeuroscienceThalamusmedicineLorazepamElectroencephalographyEEG-fMRIPsychologyNeurosciencemedicine.drugEeg alphaNeuroImage
researchProduct

Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo

2003

Udgivelsesdato: 2003-Apr The antipsychotic effect of neuroleptics cannot be attributed entirely to acute blockade of postsynaptic D(2)-like dopamine (DA) receptors, but may arise in conjunction with the delayed depolarization block of the presynaptic neurons and reduced DA synthesis capacity. Whereas the phenomenon of depolarization block is well established in animals, it is unknown if a similar phenomenon occurs in humans treated with neuroleptics. We hypothesized that haloperidol treatment should result in decreased DA synthesis capacity. We used 6-[(18)F]fluoro-L-dopa (FDOPA) and positron emission tomography (PET) in conjunction with compartmental modeling to measure the relative activi…

AdultMalePsychosismedicine.medical_specialtyPatientsDopamineDown-RegulationStatistics NonparametricDopamineInternal medicinemedicineHaloperidolHumansPharmacologybusiness.industryPutamenDopamine antagonistBrainDepolarizationHuman brainMiddle Agedmedicine.diseasePsychiatry and Mental healthEndocrinologymedicine.anatomical_structureCerebral cortexAnesthesiaSchizophreniaHaloperidolbusinessTomography Emission-Computedmedicine.drug
researchProduct

Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies

2012

[(18)F]Fallypride ([(18)F]FP) is an important and routinely used D2/D3 antagonist for quantitative imaging of dopaminergic neurotransmission in vivo. Recently it was shown that the brain uptake of the structurally related [(11)C]raclopride is modulated by P-glycoprotein (P-gp), an important efflux transporter at the blood-brain barrier. The purpose of this study was to determine whether the brain uptake of [(18)F]FP is influenced by P-gp. For examination of this possible modulation microPET studies were performed in a rat and a mouse model. Hence, [(18)F]FP was applied to Sprague Dawley rats, half of them being treated with the P-gp inhibitor cyclosporine A (CsA). In a second experimental s…

Fluorine RadioisotopesATP Binding Cassette Transporter Subfamily BStandardized uptake valueStriatumPharmacologyRats Sprague-DawleyMiceCellular and Molecular NeuroscienceCerebellummedicineAnimalsEnzyme InhibitorsReceptorP-glycoproteinMice KnockoutPharmacologyRaclopridebiologyChemistryWild typeAntagonistBrainCorpus StriatumFallypridePositron-Emission TomographyBenzamidesCyclosporinebiology.proteinRadiopharmaceuticalsmedicine.drugNeuropharmacology
researchProduct

Drug interactions at GABA(A) receptors.

2002

Neurotransmitter receptor systems have been the focus of intensive pharmacological research for more than 20 years for basic and applied scientific reasons, but only recently has there been a better understanding of their key features. One of these systems includes the type A receptor for the gamma-aminobutyric acid (GABA), which forms an integral anion channel from a pentameric subunit assembly and mediates most of the fast inhibitory neurotransmission in the adult vertebrate central nervous system. Up to now, depending on the definition, 16-19 mammalian subunits have been cloned and localized on different genes. Their assembly into proteins in a poorly defined stoichiometry forms the basi…

GABAA receptorChemistryGeneral NeuroscienceMolecular Sequence DataLoreclezoleNeurotransmissionReceptors GABA-AGABAA-rho receptorGABA AntagonistsNeurotransmitter receptormedicineAnimalsHumansDrug InteractionsAmino Acid SequenceGABA-A Receptor AgonistsGABA-A Receptor AntagonistsBinding siteReceptorGlycine receptorNeuroscienceGABA Agonistsmedicine.drugProgress in neurobiology
researchProduct

The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey

2008

AbstractThis study related clinical effects to daily doses and serum concentrations of ziprasidone by retrospective analysis of data from a therapeutic drug monitoring (TDM) survey established for patients treated with the new antipsychotic drug. In the total sample of 463 patients ziprasidone doses ranged between 20 and 320 mg/d and correlated significantly (r2 = 0.093, P &lt; 0.01) with serum concentrations. The latter were highly variable within and between individual patients (between patients median 67 ng/ml, 25–75th percentile 40–103 ng/ml). Pharmacokinetic interactions with comedication played a minor role. According to the clinical global impressions (CGI) scale most of the 348 pati…

MaleDrugmedicine.drug_classmedia_common.quotation_subjectAtypical antipsychotic030204 cardiovascular system & hematologyPharmacologySeverity of Illness Index030226 pharmacology & pharmacyDrug Administration SchedulePiperazines03 medical and health sciences0302 clinical medicinePharmacotherapyPharmacokineticsHumansMedicineZiprasidoneRetrospective Studiesmedia_commonDose-Response Relationship Drugmedicine.diagnostic_testMood Disordersbusiness.industryDrug interactionThiazolesPsychiatry and Mental healthTreatment OutcomePsychotic DisordersTherapeutic drug monitoringAnesthesiaPharmacodynamicsDrug Therapy CombinationFemaleDrug MonitoringbusinessAntipsychotic Agentsmedicine.drugEuropean Psychiatry
researchProduct

Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Moni…

1996

Venlafaxine is a new nontricyclic antidepressant inhibiting the reuptake of serotonin, noradrenaline, and, to a lesser extent, dopamine without antagonizing cholinergic, histaminergic, or noradrenergic receptors. Significantly, in a first placebo-controlled safety and efficacy study, high doses of venlafaxine increased blood pressure in some study subjects. In order to investigate further the effect of subchronic antidepressant drug treatment on blood pressure and heart rate, the effects of a conventional tricyclic (imipramine) and a structurally different phenethylamine antidepressant (venlafaxine) were compared. Sixteen inpatients with major depression (melancholic type) were treated for …

AdultMaleImipramineVenlafaxine HydrochlorideHemodynamicsBlood PressureVenlafaxineAntidepressive Agents TricyclicImipramineDouble-Blind MethodHeart RateHeart ratemedicineHumansPharmacology (medical)Psychiatric Status Rating ScalesDepressive Disorderbusiness.industryVenlafaxine HydrochlorideGeneral MedicineBlood Pressure Monitoring AmbulatoryMiddle AgedCyclohexanolsPsychiatry and Mental healthBlood pressureAnesthesiaCirculatory systemAntidepressive Agents Second-GenerationAntidepressantFemalebusinessmedicine.drugPharmacopsychiatry
researchProduct

Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli

2009

r r Abstract: Dopamine (DA) modulates the response of the amygdala. However, the relation between dopa- minergic neurotransmission in striatal and extrastriatal brain regions and amygdala reactivity to affective stimuli has not yet been established. To address this issue, we measured DA D2/D3 receptor (DRD2/3) availability in twenty-eight healthy men (nicotine-dependent smokers and never-smokers) using positron emission tomography with ( 18 F)fallypride. In the same group of participants, amygdala response to unpleasant visual stimuli was determined using blood oxygen level-dependent (BOLD) functional mag- netic resonance imaging. The effects of DRD2/3 availability in emotion-related brain …

AdultMalePyrrolidinesEmotionsNeurotransmissionAmygdalaDopamine receptor D3DopamineDopamine receptor D2medicineHumansRadiology Nuclear Medicine and imagingPrefrontal cortexResearch ArticlesBrain MappingRadiological and Ultrasound TechnologyReceptors Dopamine D2SmokingReceptors Dopamine D3Tobacco Use DisorderAmygdalaMagnetic Resonance ImagingOxygenmedicine.anatomical_structureNeurologyFallyprideCerebrovascular CirculationPositron-Emission TomographyBenzamidesVisual PerceptionAnxietyNeurology (clinical)Anatomymedicine.symptomPsychologyNeurosciencePhotic Stimulationmedicine.drug
researchProduct

Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study.

2010

Conventional indices of the utilization of FDOPA in living human brain have not consistently revealed important declines in dopamine function with normal aging. However, most methods of kinetic analysis have assumed irreversible trapping of decarboxylated FDOPA metabolites in brain, an assumption that is violated even in PET recordings of short duration. Therefore, we have developed methods for the calculation of steady-state storage of FDOPA together with its decarboxylated metabolites (V(d), mlg(-1)), based upon improved kinetic analysis of 120-min emission recordings. In a group of 28 normal male subjects, of age ranging from 23 to 73 years, the magnitude of V(d) in the striatum and in e…

AdultMalemedicine.medical_specialtyAgingMonoamine oxidaseDopamineModels NeurologicalStriatumchemistry.chemical_compoundYoung AdultDopamineInternal medicinemedicineHumansNeurotransmitterAgedCerebral CortexAromatic L-amino acid decarboxylaseChemistryGeneral NeuroscienceBrainHuman brainMiddle AgedCorpus StriatumKineticsmedicine.anatomical_structureEndocrinologyCerebral cortexPositron-Emission TomographyCatecholamineDopa DecarboxylaseNeurology (clinical)Geriatrics and GerontologyDevelopmental Biologymedicine.drugNeurobiology of aging
researchProduct

Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers

2010

Objective Cognitive functions dependent on the prefrontal cortex, such as the ability to suppress behavior (response inhibition) and initiate a new one (response re-engagement) is important in the activities of daily life. Central serotonin (5-HT) function is thought to be a critical component of these cognitive functions. In recent studies, 5-HT failed to affect stop-signal reaction time (SSRT), a fundamental process in behavioral inhibition. We were interested if response inhibition and re-engagement are influenced through central 5-HT activity as mediated via the 5-HT transporter. Methods Here, using a stop-change task, we investigated the effects of acute and repeated treatment with 10 …

AdultMaleSerotoninCitalopramCitalopramSerotonergicDrug Administration ScheduleDevelopmental psychologyDouble-Blind MethodReaction TimemedicineHumansEscitalopramPharmacology (medical)Prefrontal cortex5-HT receptorCross-Over StudiesDose-Response Relationship DrugCognitionInhibition PsychologicalPsychiatry and Mental healthNeurologyNeurology (clinical)SerotoninReuptake inhibitorPsychologyNeuroscienceSelective Serotonin Reuptake Inhibitorsmedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET inves…

2006

Dopamine neurotransmission influences those cognitive processes, which are generally regarded as prefrontal cortical functions. In previous positron‐emission‐tomography (PET) studies, net blood‐brain clearance of [(18)F]‐fluoro‐l‐DOPA (FDOPA) correlated with impaired cognitive performance in patients with Parkinson's disease or schizophrenia. We hypothesized that FDOPA influx also correlates with performance of cognitive tasks associated with prefrontal functioning in healthy volunteers. The net blood‐brain clearance of FDOPA (K [Formula: see text]) was mapped in a group of 11 healthy volunteers and calculated in striatal volumes‐of‐interest. The Wisconsin‐Card‐Sorting‐Test (WCST), Stroop‐T…

AdultMaleElementary cognitive taskMetabolic Clearance RateDopamineCaudate nucleusPrefrontal CortexStriatumNeuropsychological Testsbehavioral disciplines and activitiesSynaptic TransmissionBasal GangliaFunctional LateralityCognitionMesencephalonReference ValuesBasal gangliaNeural PathwaysReaction TimeHumansRadiology Nuclear Medicine and imagingPrefrontal cortexResearch ArticlesBrain MappingRadiological and Ultrasound TechnologyReceptors Dopamine D2PutamenCognitive flexibilityPutamenMiddle AgedDihydroxyphenylalanineNeurologyBlood-Brain BarrierPositron-Emission TomographyNeurology (clinical)AnatomyCaudate NucleusPsychologyNeuroscienceStroop effectHuman brain mapping
researchProduct

Diagnostik von ZNS-Erkrankungen mittels PET bzw. SPECT: Radiopharmazeutische Strategien und klinische Anwendungen

2005

Radioaktiv markierte Molekule fur die nicht-invasive Darstellung biochemischer Funktionen haben seit etwa 25 Jahren betrachtlich zum Verstandnis normaler und gestorter Stoffwechselvorgange im Hirn beigetragen. In einigen Fallen hat dies dazu gefuhrt, dass 18F-markierte PET- bzw. 123I- und 99mTc-Radiodiagnostika ihren festen Platz bei der klinischen Diagnostik von Erkrankungen des Zentralen Nervensystems mittels der modernen tomographischen Techniken PET bzw. SPECT gefunden haben. Dies betrifft primar den Mb. Parkinson, die Epilepsie, zunehmend die Alzheimer Demenz, aber auch Hirntumore. Diese molekulare, neurochemische Diagnostik in vivo wird, in Konkurrenz zu etablierten klinischen Diagnos…

Pharmacologybusiness.industryPharmaceutical ScienceMedicinePharmacology (medical)Nuclear medicinebusinessPharmazie in unserer Zeit
researchProduct

Association of Low Striatal Dopamine D2Receptor Availability With Nicotine Dependence Similar to That Seen With Other Drugs of Abuse

2008

All drugs of abuse induce a phasic dopamine release within the striatum that does not undergo habituation. Prolonged substance consumption impairs the natural function of the mesolimbic dopamine system, as shown by a decrease in the availability of striatal dopamine 2 (D(2)) receptors in patients suffering from cocaine, heroin, amphetamine, and alcohol dependence. However, it is unclear whether similar changes can also be observed in heavy-smoking nicotine-dependent smokers.In vivo D(2)/D(3) receptor availability was determined with [ (18)F]fallypride positron emission tomography in 17 heavy-smoking nicotine-dependent subjects and in 21 age-matched never-smoking comparison subjects. The smo…

AdultMaleFluorine Radioisotopesmedicine.medical_specialtyPyrrolidinesSubstance-Related DisordersStriatumGyrus CinguliBasal GangliaFunctional LateralityNicotineDopamineInternal medicineDopamine receptor D2medicineHumansCarbon RadioisotopesAmphetamineReceptors Dopamine D2PutamenSmokingReceptors Dopamine D3Tobacco Use DisorderTemporal LobeSubstance Withdrawal SyndromeBehavior AddictivePsychiatry and Mental healthEndocrinologyFallyprideDopamine receptorPositron-Emission TomographyBenzamidesPsychologymedicine.drugAmerican Journal of Psychiatry
researchProduct

Dopamine-modulated aversive emotion processing fails in alcohol-dependent patients.

2013

Negative mood states after alco- hol detoxifi cation may enhance the relapse risk. As recently shown in healthy volunteers, dopamine storage capacity ( V d ) in the left amy- gdala was positively correlated with functional activation in the left amygdala and anterior cin- gulate cortex (ACC) during an emotional task; high functional connectivity between the amy- gdala and the ACC, a region important for emo- tion regulation, was associated with low trait anxiety. Based on these fi ndings, we now tested whether detoxifi ed alcohol-dependent patients have a disrupted modulation of the anterior cin- gulate cortex activation in response to aversive stimuli by amygdala dopamine. Furthermore, we …

AdultMaleDopamineEmotionsAnxietyAmygdalaNeuroimagingDopaminemedicineImage Processing Computer-AssistedHumansPharmacology (medical)Cerebral Cortexmedicine.diagnostic_testSmokingMagnetic resonance imagingGeneral MedicineAmygdalaMagnetic Resonance ImagingCortex (botany)Diagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthAffectAlcoholismmedicine.anatomical_structurePositron emission tomographyPositron-Emission TomographyAnxietyFemalemedicine.symptomAversive StimulusRadiopharmaceuticalsPsychologyNeurosciencepsychological phenomena and processesPhotic Stimulationmedicine.drugPharmacopsychiatry
researchProduct